Khashayar Esfahani

2.8k total citations · 2 hit papers
37 papers, 1.3k citations indexed

About

Khashayar Esfahani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Khashayar Esfahani has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Khashayar Esfahani's work include Cancer Immunotherapy and Biomarkers (8 papers), Head and Neck Cancer Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Khashayar Esfahani is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Head and Neck Cancer Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Khashayar Esfahani collaborates with scholars based in Canada, United States and Iran. Khashayar Esfahani's co-authors include Wilson H. Miller, Neha Papneja, Liya Roudaia, Sonia V. del Rincón, Marie Hudson, Réjean Lapointe, Arielle Elkrief, Leonard H. Calabrese, Bertrand Routy and Cassandra Calabrese and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Khashayar Esfahani

34 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future

2020 693 citations Khashayar Esfahani, Liya Roudaia et al. Current Oncology profile →
Moving towards personalized treatments of immune-related adverse events

2020 229 citations Khashayar Esfahani, Arielle Elkrief et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Khashayar Esfahani Canada	11	741	430	374	203	152	37	1.3k
Lucy Boyce Kennedy United States	8	715 1.0×	478 1.1×	343 0.9×	235 1.2×	192 1.3×	20	1.3k
Sofia Farkona Canada	8	517 0.7×	444 1.0×	284 0.8×	119 0.6×	151 1.0×	13	983
Danny N. Khalil United States	14	950 1.3×	637 1.5×	410 1.1×	274 1.3×	269 1.8×	40	1.6k
Sreya Bagchi United States	10	984 1.3×	778 1.8×	512 1.4×	370 1.8×	136 0.9×	14	1.8k
Caterina Ieranò Italy	20	917 1.2×	462 1.1×	546 1.5×	119 0.6×	61 0.4×	34	1.4k
Kwan‐Hwa Chi Taiwan	24	680 0.9×	366 0.9×	494 1.3×	336 1.7×	175 1.2×	63	1.8k
Navid Sobhani Italy	21	607 0.8×	294 0.7×	556 1.5×	416 2.0×	95 0.6×	58	1.3k
Matthew W. Vanneman United States	10	956 1.3×	903 2.1×	552 1.5×	220 1.1×	250 1.6×	35	1.9k
Weiye Deng United States	19	623 0.8×	377 0.9×	419 1.1×	381 1.9×	200 1.3×	43	1.5k
Robert Yuan United States	8	1.0k 1.4×	794 1.8×	666 1.8×	376 1.9×	145 1.0×	10	1.9k

Countries citing papers authored by Khashayar Esfahani

Since Specialization

Citations

This map shows the geographic impact of Khashayar Esfahani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khashayar Esfahani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khashayar Esfahani more than expected).

Fields of papers citing papers by Khashayar Esfahani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khashayar Esfahani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khashayar Esfahani. The network helps show where Khashayar Esfahani may publish in the future.

Co-authorship network of co-authors of Khashayar Esfahani

This figure shows the co-authorship network connecting the top 25 collaborators of Khashayar Esfahani. A scholar is included among the top collaborators of Khashayar Esfahani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khashayar Esfahani. Khashayar Esfahani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Esfahani, Khashayar, Khalil Sultanem, Jonathan Spicer, et al.. (2025). “Tension Chyle Leak”: A Life‐Threatening Sequela of Thoracic Duct Injury Following Resection of BRAF ‐Mutated Anaplastic Thyroid Carcinoma. Head & Neck. 47(6). E64–E67.

Baines, Kelly J., Wilson H. Miller, Rahima Jamal, et al.. (2025). Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. Journal for ImmunoTherapy of Cancer. 13(8). e012659–e012659. 2 indexed citations

Hashemi, Mehrdad, Nafiseh Sharifi, Khashayar Esfahani, et al.. (2025). SIRT1 as a masterful reciprocal regulator of molecular mechanisms and signaling pathways involved in tumor growth and expansion. Clinical and Experimental Medicine. 25(1). 225–225. 2 indexed citations

Esfahani, Khashayar, et al.. (2024). A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine. Current Oncology. 31(4). 1913–1919. 3 indexed citations

Mascarella, Marco A., Shaum Sridharan, Khalil Sultanem, et al.. (2024). Sarcopenia predicts short‐term treatment‐related toxicity in patients undergoing curative‐intent therapy for head and neck cancer: A systematic review and meta‐analysis. Head & Neck. 46(6). 1500–1509. 5 indexed citations

Mascarella, Marco A., Keith Richardson, Alex Mlynarek, et al.. (2024). Neoadjuvant Capecitabine in Operable HPV‐Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting. Otolaryngology. 171(6). 1773–1779.

Mascarella, Marco A., Khalil Sultanem, Christina Tsien, et al.. (2024). Predicting short-term treatment toxicity in head and neck cancer through a systematic review and meta-analysis. Journal of Geriatric Oncology. 15(8). 102064–102064. 1 indexed citations

Sadeghi, Nader, Keith Richardson, Marco A. Mascarella, et al.. (2024). Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus–Related Oropharyngeal Cancer. JAMA Otolaryngology–Head & Neck Surgery. 151(2). 128–128. 1 indexed citations

Esfahani, Khashayar, et al.. (2024). A Review of Immunotherapy in Non-Small-Cell Lung Cancer. Current Oncology. 31(6). 3495–3512. 7 indexed citations

10.

Esfahani, Khashayar, Paulo Rogério Ferreti Bonan, Michael Hier, et al.. (2024). Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer. International Journal of Molecular Sciences. 25(7). 4009–4009. 2 indexed citations

11.

Esfahani, Khashayar, Arielle Elkrief, Cassandra Calabrese, et al.. (2020). Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology. 17(8). 504–515. 229 indexed citations breakdown →

12.

Esfahani, Khashayar, et al.. (2020). A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Current Oncology. 27(12). 87–97. 693 indexed citations breakdown →

13.

Esfahani, Khashayar, Nicholas Meti, Wilson H. Miller, & Marie Hudson. (2019). Adverse events associated with immune checkpoint inhibitor treatment for cancer. Canadian Medical Association Journal. 191(2). E40–E46. 46 indexed citations

14.

Esfahani, Khashayar, Tho-Alfakar Al-Aubodah, Paméla Thébault, et al.. (2019). Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nature Communications. 10(1). 4712–4712. 82 indexed citations

15.

Esfahani, Khashayar, Goulnar Kasymjanova, Jason Agulnik, et al.. (2019). A phase I open prospective cohort trial of curcumin plus tyrosine kinase inhibitors for EGFR-mutant advanced non-small cell lung cancer.. Journal of Clinical Oncology. 37(15_suppl). e20611–e20611. 8 indexed citations

16.

Esfahani, Khashayar, et al.. (2018). The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers. 10(6). 204–204. 32 indexed citations

17.

Nikonova, Anna S., Khashayar Esfahani, Stephan Probst, et al.. (2017). Erdheim-Chester Disease: The Importance of Information Integration. Case Reports in Oncology. 10(2). 613–619. 5 indexed citations

18.

Cohen, Victor & Khashayar Esfahani. (2016). HSP90 as a novel molecular target in non-small-cell lung cancer. PubMed. 7. 11–11. 22 indexed citations

19.

Ferrario, Cristiano, Khashayar Esfahani, Adrian Langleben, et al.. (2016). Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. PLoS ONE. 11(12). e0167906–e0167906. 10 indexed citations

20.

Esfahani, Khashayar, et al.. (2014). The Trastuzumab and Vinorelbine Combination: An Alternative to Taxane-Based Chemotherapy for Early-Stage and Locally Advanced HER2-Positive Breast Cancer. Current Oncology. 21(5). 723–727. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact